ICO L Hospitalet ( Site 1305)

L'Hospitalet de Llobregat, Barcelona 08908

0 studies enrolling now · 1 studies all time

What they study most

Triple Negative Breast Neoplasms

Studies at this site

• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) — Completed